To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

NCT03656393 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
EGFR

Interventions

DRUG: Gefitinib
DRUG: Vinorelbine
DRUG: Carboplatin

Sponsor

Shenzhen People's Hospital